ArticleFrontiers in genetics2011
The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies.
Article in Frontiers in genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Long non-coding RNA as potential diagnostic markers for acute myeloid leukemia: A systematic review and meta-analysis.Cancer medicine · 2024Pooled it
- Association of lncRNA THRIL, HOTAIR genes variations and expression levels with pulmonary tuberculosis.BMC medical genomics · 2023Article
- Role of non‑coding RNA intertwined with the Wnt/β‑catenin signaling pathway in endometrial cancer (Review).Molecular medicine reports · 2023Review
- Research progress on epigenetics of small B-cell lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.Blood advances · 2017Article
- TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population.Oncotarget · 2017Article
- miR-34b Targets HSF1 to Suppress Cell Survival in Acute Myeloid Leukemia.Oncology research · 2016Article
- A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.Oncogene · 2015Article
- Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets.BioMed research international · 2015Review
- Deletion of the miR-143/145 cluster leads to hydronephrosis in mice.The American journal of pathology · 2014Article
- Mir-218 contributes to the transformation of 5-Aza/GF induced umbilical cord mesenchymal stem cells into hematopoietic cells through the MITF pathway.Molecular biology reports · 2014Article
- The up-regulation of miR-199b-5p in erythroid differentiation is associated with GATA-1 and NF-E2.Molecules and cells · 2014Article
- MicroRNAs in sensorineural diseases of the ear.Frontiers in molecular neuroscience · 2013Review
- Long non-coding RNAs in hematologic malignancies: road to translational research.Frontiers in genetics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The field of non-coding RNAs (ncRNAs) encompasses a wide array of RNA classes that are indispensible for the regulation of cellular activities. However, de-regulation of these ncRNAs can also play key roles in malignant transformation and cancer cell behavior. In this article we survey a select group of microRNAs and long ncRNAs that appear to contribute in keys ways to the development of acute and chronic leukemias, as well as contribute to their diagnosis, prognosis, and potentially, their treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.